NCT03841617 2026-04-14
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
22 trialsNCT03244956 2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT02145143 2025-06-18
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT06431620 2024-05-28
Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer
Nanjing First Hospital, Nanjing Medical University
Phase NA Recruiting
NCT06405217 2024-05-08
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
Nanjing First Hospital, Nanjing Medical University
Phase NA Recruiting
NCT04971473 2024-03-28
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Completed
NCT04137185 2024-03-06
Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Completed
NCT00415233 2023-12-19
HiLo
University College, London
Phase 3 Unknown
NCT04447183 2023-10-23
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Unknown
NCT04964284 2023-10-23
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01837745 2023-05-17
ESTIMABL2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Active not recruiting
NCT03276988 2020-09-09
Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients
Genexine, Inc.
Phase 1/2 Completed
NCT02278198 2019-10-24
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
University of Colorado, Denver
Phase 1 Completed
NCT00085293 2018-11-29
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Phase 2 Completed
NCT00181168 2018-11-02
Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Johns Hopkins University
Phase 2 Completed
NCT00196729 2015-03-18
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
Sanofi
Phase 3 Completed
NCT00295763 2015-03-18
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Sanofi
Phase 3 Completed
NCT00604318 2013-01-10
Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
Copenhagen University Hospital at Herlev
Phase 4 Completed
NCT00001730 2008-03-04
Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.
National Institutes of Health Clinical Center (CC)
Phase 4 Completed
NCT00435851 2007-02-19
Estimabl
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Unknown